Uptake of anti-anemic substance ferric-sorbitol-citrate by normal and malignant cells and its effects on expression of transferrin receptor 1 and ferritin

Cancer Biotherapy and Radiopharmaceuticals

Volumn 21, Issue 6, 2006, Pages 636-644

  Prutki, Maja ^a   Poljak Blazi, Marija ^b   Mihaljevic, Branka ^b   Orescanin, Visnja ^b   Zarkovic, Neven ^b  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Carcinoma cells; Ferric sorbitol citrate; Ferritin; Iron metabolism; Lipid peroxidation; Transferrin receptor 1

Indexed keywords

ANTIANEMIC AGENT; CD71 ANTIGEN; FERRIC SORBITOL CITRATE; FERRITIN; IRON SORBITEX; PROTEIN BCL 2; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER REGRESSION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TUMOR LEVEL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRON OVERLOAD; LIPID PEROXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; SIGNAL TRANSDUCTION;

ANEMIA; ANTIGENS, CD; CELL LINE; CITRATES; CULTURE MEDIA; FERRIC COMPOUNDS; FERRITINS; GENE EXPRESSION; HUMANS; IRON; LIPID PEROXIDATION; LIPID PEROXIDES; NEOPLASMS; RECEPTORS, TRANSFERRIN;

EID: 33846595140     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2006.21.636     Document Type: Article

References (32)

1. Gackowski D, Kruszewski M, Banaskziewicz Z, et al. Lymphocyte labile iron pool, plasma iron, transferrin saturation, and ferritin levels in colon cancer patients. Acta Biochim Pol 2002;49:269.
2. Richardson DR, Ponka P. The molecular mechanism of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta 1997;1331:1.
3. Gatter KC, Brown G, Trowbridge IS, et al. Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J Clin Pathol 1983;36:539.
4. Balla G, Jacob JS, Balla J, et al. Ferritin: A cytoprotective antioxidant stratagem of endothelium. J Biol Chem 1992;267:18148.
5. White S, Teatle R, Seligman PA, et al. Combinations of antitransferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: Evidence for synergistic antiproliferative effects. Cancer Res 1990;50:6295.
6. Blatt J, Taylor SR, Kontoghiorghes GR. Comparison of activity of deferoxamine with that of oral iron chelators against human neuroblastoma cell lines. Cancer Res 1989;49:2925.
7. Poljak-Blazi M, Kralj M, Popovic-Hadzija M. Oncogene activation and apoptosis as possible mechanism of antitumour effect of ferric-sorbitol-citrate. In: Roussel AM, Anderson RA, Favier AE, eds. Proceedings of TEMA 10. New York: Cluwer Academic/Plenum Publisher, 2000:123.
8. Poljak-Blazi M, Zarkovic N, Schaur RJ. Impaired proliferation and DNA synthesis of a human tumor cell line (HeLa) caused by a short treatment with FSC and the lipid peroxidation product 4-hydroxinonenal. Cancer Biother Radioph 1998;13:395.
9. Poljak-Blazi M, Stancic-Rokotov D, Ferle-Vidovic A. Inhibitory effect of iron on melanoma B16 growth. Period Biol 1985;87:17.
10. Flajsig I, Poljak-Blazi M. Influence of iron on proliferation and cell-cycle kinetics on cultured malignant and nonmalignant cell. Oncology 1990;47:443.
11. Lederman HM, Cohen A, Lee JW, et al. Deferoxamine: A reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1984;64:748
12. Whitney JF, Clare JM, Griffin TW, et al. Transferrin receptor expression in non-small-cell lung cancer: Histopathologic and clinical correlates. Cancer 1995; 76:20.
13. Yang HB, Hsu PI, Lee JC, et al. Adenoma-carcinoma sequence; A reappraisal with immunohistochemical expression of ferritin. J Surg Oncol 1995;60:35.
14. Wagner CD, Clever HL, Peters ED. Evaluation of the ferrous thiocyanate colorimetric method. Anal Chem 1947;19:980.
15. Tsoukalas B, Grosch W. Analysis of fat deterioration-comparison of some photometric tests. J Am Oil Chem Soc 1997;54:490.
16. Mihaljevic B, Katusin-Razem B, Razem D. The reevaluation of the ferric thiocyanate assay for lipid hydroperoxides with special considerations of the mechanistic aspects of the response. Free Rad Biol Med 1996;21:53.
17. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996;5:19.
18. Craven CM, Alexander J, Eldridge M, et al. Tissue distribution and clearance kinetics of non-transferrin-bound iron in the hypotransferrinemic mouse: A rodent model for hemochromatosis. Proc Natl Acad Sci USA 1987;84:3457.
19. Poljak-Blazi M, Kralj M, Popovic Hadzija M, et al. Involvement of lipid peroxidation, oncogene expression, and induction of apoptosis in the antitumorous activity of ferric-sorbitol-citrate. Cancer Biother Radiopharm 2000;15:285.
20. Yeh CJ, Papamichael M, Faulk WP. Loss of transferrin receptors following induced differentiation of HL-60 promyelocytic leukemia cells. Exp Cell Res 1982;138:439.
21. O'Connell M, Halliwell B, Moorhouse CP, et al. Formation of hydroxyl radicals in the presence of ferritin and haemosiderin: Is haemosiderin formation a biological protective mechanism? Biochem J 1986;15:727.
22. Halliwell B, Gutteridge JM, Cross C. Free radicals, antioxidants, and human disease: Whee are we now? J Lab Clin Med 1992;119:598.
23. Cazzola M, Bergamaschi G, Dezza L, et al. Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: Achievements and prospects. Blood 1990;75:1903.
24. Tadolini B, Cabrini L, Menna C, et al. Iron(III) stimulation of lipid hydroperoxide-dependent lipid peroxidation. Free Rad Res 1997;27:563.
25. Goldstein G, Czapski G. Mannitol as an OH · scavenger in aqueous solutions and in biological systems. Int J Radiat Biol 1984;46:725.
26. Zarkovic N, Ilić Z, Jurin M, Scahur RJ, et al. Stimulation of HeLa cell growth by physiological concentrations of 4-hydroxynonenal. Cell Biochem Funct 1993; 11:279.
27. Zarkovic N, Zarkovic K, Schaur RJ, et al. 4-hydroxynonenal as a second messenger of free radicals and growth-modifying factor. Life Sci 1999;65:1901.
28. Zarkovic N. 4-hydroxynonenal as a bioactive marker of pathopysiological processes. Mol Asp Med 2003;24:281.
29. Biasi F, Tessitore L, Zanetti D, et al. Associated changes of lipid peroxidation and TGFβ1 levels in human cancer during tumor progression. Gut 2002; 50:361.
30. Zarkovic K, Uchida K, Kolenc D, et al. Tissue distribution of lipid peroxidation product acrolein in human colon carcinogenesis. Free Rad Res 2006;40:543.
31. Biasi F, Vizio B, Mascia C, et al. JNK upregulation as a key event in the proapoptotic interaction between TGF-β1 and 4-hydroxynonenal in colon mucosa. Free Rad Biol Med 2006;40:443.
32. Prutki M, Poljak-Blazi M, Jakopovic M, et al. Altered iron metabolism, transferrin receptor 1, and ferritin in patients with colon cancer. Cancer Lett 2006;238:188.